Costello syndrome (CS) is a RASopathy caused by activating germline mutations in HRAS. Due to ubiquitous HRAS gene expression, CS affects multiple organ systems and individuals are predisposed to cancer. Individuals with CS may have distinctive craniofacial features, cardiac anomalies, growth and developmental delays, as well as dermatological, orthopedic, ocular, and neurological issues; however, considerable overlap with other RASopathies exists. Medical evaluation requires an understanding of the multifaceted phenotype. Subspecialists may have limited experience in caring for these individuals because of the rarity of CS. Furthermore, the phenotypic presentation may vary with the underlying genotype. These guidelines were developed by an interdisciplinary team of experts in order to encourage timely health care practices and provide medical management guidelines for the primary and specialty care provider, as well as for the families and affected individuals across their lifespan. These guidelines are based on expert opinion and do not represent evidence-based guidelines due to the lack of data for this rare condition.

Additional Metadata
Keywords Costello syndrome, HRAS mutation, management guidelines, RAS/MAPK, RASopathy
Persistent URL dx.doi.org/10.1002/ajmg.a.61270, hdl.handle.net/1765/119466
Journal American Journal of Medical Genetics. Part A
Citation
Gripp, K.W, Morse, L.A., Axelrad, M., Chatfield, K.C., Chidekel, A., Dobyns, W.B, … Rauen, K.A. (2019). Costello syndrome: Clinical phenotype, genotype, and management guidelines. American Journal of Medical Genetics. Part A, 179(9), 1725–1744. doi:10.1002/ajmg.a.61270